Cerenis Therapeutics provided updates on its clinical advancements. The company is finalizing a phase 2 study, in post-Acute Coronary Syndrome (post-ACS) patients. The company is also pursuing TANGO, a phase 3 study for patients with HDL deficiency due to defects in genes coding for apolipoprotein A-I and ABCA1, for which Cerenis Therapeutics has been granted two orphan drug designations by the European Medicines Agency. Cerenis Therapeutics received FDA IND approval to begin studies with CER-209. Fourth quarter 2016 clinical advancements: Cerenis therapeutics received FDA IND approval to begin studies with CER-209 in NAFLD and NASH. U.S. Food and Drug Administration (FDA) informed Cerenis Therapeutics that clinical trials with CER-209 may proceed. The Investigational New Drug application (IND) for CER-209 includes plans for a Phase 1 clinical study of its P2Y13 receptor agonist drug candidate (CER-209) in healthy volunteers for the clinical investigation of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). CER-209, a selective novel agonist of the P2Y13 receptor, induced a decrease in atherosclerotic plaques in aorta and carotids as well as a remarkable decrease in steatosis in validated preclinical models. Cerenis plans to begin enrollment in first quarter 2017. CER-001’s last patient dosed in CARAT study: Enrollment was completed in August 2016 and the last patient received the tenth and final infusion of CER-001 or placebo in fourth quarter 2016. The company expects to report CARAT study results by the end of 2017 first quarter. The persistent risk of recurrence of a heart attack for patients who have just experienced an ACS event remains very high and represents a significant and unmet medical need. CER-001 would provide a unique opportunity to reduce the risk of recurrent cardiovascular events during the first few months following an ACS event by enabling the rapid regression of atherosclerotic plaque. CER-001, in addition to long-term LDL-C lowering treatments, could enable further reductions in morbidity and mortality and could consequently become the new standard of care for treating patients following an ACS. Update regarding TANGO trial: Active enrollment in the phase 3 TANGO trial continues. The Company has engaged 18 sites worldwide to optimize the availability of patients with Familial Primary Hypo-Alphalipoproteinemia (FPHA), a rare but clinically important orphan disease.